Leverages a nearly 20‑year, ~2,000‑member founder‑heavy network (70% founders/CEOs, 20% pre‑seed/seed VCs, 10% execs), a founders‑first ecosystem, and a repeatable playbook to commercialize defense and deep‑tech R&D. The firm continues to build its presence across the venture capital landscape.
Ranked by shared stages, industries, geography, cheque size and investor type. 400 related investors in the directory.
Crypto-native operators who architect token-first ecosystems via token design, governance, and collective bootstrapping, empowering founders construct enduring token economies from day one and backing 100+ on-chain projects.
Formative-stage investor oriented toward AI-driven health, mobility, fintech/insurtech and intelligent enterprise, delivering hands-on GTM and roadmap support from ex-corporate venture leaders and engineers leveraging Allianz's risk, data, and regulatory expertise. With a disciplined investment approach, the team drives value for both founders and investors.
Builds AI companies from inception alongside recruited CEOs, acting as an AI R&D studio that sources ideas with large corporates to deliver agentic-AI ventures with built-in customers and traction. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Offers strictly non-dilutive term loans without warrants, tailored to B2B SaaS businesses in the $1M to $10M ARR range. The firm prioritizes capital-efficient, niche vertical SaaS companies and openly shares its revenue-financing frameworks and underwriting methodologies.
Deliberate 60/40 tech/healthcare split dedicated to de novo company formation, with a transparent debate-driven partner scoring system (1–4) and proven multi-generation continuity. With a clear focus on healthcare innovation, the firm brings both capital and domain expertise.
Is dedicated to impactful businesses aiming to positively transform the world's food system.
